Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's announcement Aug. 24 that it is reviewing adverse event reports of liver injury related to orlistat - the active ingredient in GlaxoSmithKline's weight-loss product alli could threaten the drug's already slipping sales.

You may also be interested in...

Obesity Drug Developers Aim To Navigate Regulatory Backroads

The major lesson of FDA’s serial rejection of three obesity drugs in a six-month span is that safety is paramount in the weight loss space. That’s agreed. But beyond that, it’s tough to know what to expect, and obesity drug developers face an uncertain regulatory path going forward.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts